BioSpace News Archive

The Healthy Paws Foundation is proud to shine a light on organizations that have similar missions as their own: to save homeless pets with essential medical care and adoption services for forever homes.

Out-of-the-box solution enables health departments to scale quickly and provide streamlined services to communities more efficiently

You could say the beauty biz was in her DNA.

OBN (UK) Ltd, the membership organisation that supports the life sciences industry, is delighted to announce the success of their 2nd annual BioSeed® event held on Wednesday,16 January 2019, at Level 39 in Canary Wharf, London.

CAMBRIDGE and BOSTON, Mass. and BERLIN, Germany, January 22, 2019 / CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and ProBioGen, a premier German service and technology provider, today announced a multi-year research collaboration focused on the development of novel in vivo delivery modalities for CRISPR/Cas9 leveraging ProBioGen’s existing technology and expertise.

The US$ 1.78 billion actigraphy sensor and PSG devices market on course to grow at 4.3% in 2019, according to Fact.MR’s latest analysis.

Pulmonary fibrosis patients, their loved ones and care team can now connect through a platform jointly launched by the Pulmonary Fibrosis Foundation (PFF) and Responsum Health.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced positive topline data from an ongoing long-term extension study of UX007 in patients with long-chain fatty acid oxidation disorder (LC-FAOD), demonstrating sustained reductions in the duration and frequency of major clinical events (MCE) and a long-term safety profile similar to what has previously been seen with UX007.

PHARMASEAL, a new provider of clinical trial management and governance solutions to enter the market, has launched EngilityÔ CTMS, the first product to be released from its Engility B2B platform.

- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the U.S. Food and Drug Administration (FDA) has completed its review of the Company’s Investigational New Drug (IND) application for AMT-130, and the IND is now effective allowing uniQure to begin its planned Phase I/II study.